Skip to main content
. 2020 Sep 19;46:102512. doi: 10.1016/j.msard.2020.102512

Table 4.

Health behavior changes due to COVID-19.

Participant sex Male Female
Age group (years) <=55 >55 <=55 >55
n Participants (% of 1,019) 87 (9) 116 (11) 420 (41) 390 (38)
Last reported date of DMT was >30 days prior to surveyan(%) 20 (23) 53 (74) 125 (30) 163 (42)
For those who have not taken DMT in last 30 days, which DMTb:
  • -

    Glatiramer acetate

  • -

    Interferon beta-1

  • -

    Peginterferon beta-1a

  • -

    Fingolimod

  • -

    Siponimod

  • -

    Dimethyl fumarate

  • -

    Teriflunomide

  • -

    Natalizumab

  • -

    Alemtuzumab
0
0
0
3 (3)
0
2 (2)
0
4 (5)
1 (1)
1 (1)
2 (2)
1 (1)
1 (1)
0
0
0
0
0
2 (0.5)
0
3 (0.7)
1 (0.2)
0
2 (0.5)
0
18 (4)
6 (1)
1 (0.3)
3 (0.8)
1 (0.3)
1 (0.3)
1 (0.3)
2 (0.5)
2 (0.5)
16 (4)
0
Changes as a result of COVID-19c:
  • -

    Delayed 1+ dose of DMT

  • -

    Delayed starting a DMT

  • -

    Stopped taking DMT

  • -

    Changed DMT

  • -

    No changes
7 (8)
3 (3)
1 (1)
0
68 (78)
6 (5)
1 (1)
2 (2)
0
62 (53)
20 (5)
6 (1)
5 (1)
3 (0.7)
300 (71)
32 (8)
7 (2)
5 (1)
2 (0.5)
215 (55)
Healthcare provider input into DMT decision:
  • -

    Patient decision

  • -

    Mutual decision

  • -

    Healthcare provider made decision
2 (2)
6 (7)
3 (3)
1 (1)
8 (7)
0
9 (2)
10 (2)
14 (3)
13 (3)
19 (5)
13 (3)
Which DMT have you stopped or changed:
  • -

    Fingolimod

  • -

    Siponimod

  • -

    Dimethyl fumarate

  • -

    Teriflunomide

  • -

    Rituximab

  • -

    Ocrelizumab
1 (1)
0
0
0
0
0
0
0
0
0
0
2 (2)
0
0
3 (0.7)
1 (0.2)
0
2 (0.5)
0
1 (0.3)
1 (0.3)
2 (0.5)
1 (0.3)
1 (0.3)
Which DMT have you delayed starting c
  • -

    Glatiramer acetate

  • -

    Interferon beta-1

  • -

    Fingolimod

  • -

    Siponimod

  • -

    Dimethyl fumarate

  • -

    Diroximel fumarate

  • -

    Teriflunomide

  • -

    Cladribine

  • -

    Natalizumab

  • -

    Ocrelizumab

  • -

    Alemtuzumab

  • -

    Otherd


0
0
0
1 (1)
0
0
0
0
0
2 (2)
0
0
0
0
0
0
0
0
0
1 (1)
0
2 (2)
0
1 (1)
0
1 (0.2)
1 (0.2)
1 (0.2)
0
1 (0.2)
1 (0.2)
2 (0.5)
1 (0.2)
3 (0.7)
1 (0.2)
0
2 (0.5)
0
0
1 (0.3)
1 (0.3)
1 (0.3)
0
1 (0.3)
0
8 (2)
1 (0.3)
1 (0.3)
For which DMT have you delayed at least one dose due to COVID-19?
  • -

    Glatiramer acetate

  • -

    Interferon beta-1

  • -

    Fingolimod

  • -

    Dimethyl fumarate

  • -

    Teriflunomide

  • -

    Cladribine

  • -

    Natalizumab

  • -

    Rituximab

  • -

    Ocrelizumab

  • -

    Other
0
0
0
0
0
0
2 (2)
1 (1)
4 (5)
0
0
0
1 (1)
0
0
0
1 (1)
1 (1)
3 (3)
0
0
0
4 (1)
0
1 (0.2)
0
4 (1)
1 (0.2)
9 (2)
1e(0.2)
1 (0.3)
1 (0.3)
3 (0.8)
2 (0.5)
1 (0.3)
1 (0.3)
5 (1)
1 (0.3)
17 (4)
0
Experienced difficulties or delays due to COVID-19c:
  • -

    Getting DMT prescription filled

 0 0 11 (3) 8 (2)
  • -

    Getting infusion of a DMT

 1 (1) 4 (3) 23 (5) 14 (4)
  • -

    Getting monitoring/safety tests performed for DMT

 7 (8) 3 (3) 37 (9) 12 (3)
  • -

    Accessing medications other than DMTs

 6 (7) 4 (3) 47 (11) 19 (5)
  • -

    Obtaining medical equipment

 0 3 (3) 10 (2) 4 (1)
  • -

    Having medical procedures performed

 15 (17) 25 (22) 74 (18) 71 (18)
  • -

    Accessing complementary/alternative services

 10 (11) 13 (11) 96 (23) 57 (15)
  • -

    Accessing complementary/alternative products

 4 (5) 4 (3) 24 (6) 16 (4)
  • -

    None

 57 (66) 78 (67) 234 (56) 244 (63)
Changes to healthcare due to COVID-19:
  • -

    Postponed or canceled a neurologist visit

 16 (18) 23 (20) 94 (22) 86 (22)
  • -

    Postponed or canceled MRIs

 10 (11) 9 (8) 59 (14) 33 (8)
  • -

    Postponed or canceled other medical visits

 32 (37) 60 (52) 190 (45) 216 (55)
  • -

    Postponed or canceled laboratory/blood tests

 12 (14) 20 (17) 92 (22) 86 (22)
  • -

    None

 43 (49) 49 (42) 157 (37) 121 (31)
Had telehealth visits as a result of COVID-19:
  • -

    Yes

  • -

    No

  • -

    Unsure
33 (38)
54 (62)
0
45 (39)
70 (60)
1 (1)
169 (40)
249 (59)
2 (0.5)
132 (34)
255 (65)
3 (0.8)

aOnly participants who reported taking a DMT in the last year were asked this question. Participants who took cladribine, ocrelizumab, or rituximab were excluded from this analysis. b98 participants <=55 years old did not have DMT data. 180 participants >55 years old did not have DMT data. cOnly participants who reported taking a DMT in the last year were asked this question. Participants chose multiple answers if they were appropriate. d1 ozanimod, 1 unknown and 1 undecided. eParticipant is in a clinical trial, drug unknown to participant.